Literature DB >> 22294526

Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series.

G Roubaud1, M Kind2, J-M Coindre3, R G Maki4, B Bui1, A Italiano1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22294526     DOI： 10.1093/annonc/mdr631

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.

Authors:  Hyung Soon Park; Sun Min Lim; Sora Kim; Sangwoo Kim; Hye Ryun Kim; KyuBum Kwack; Min Goo Lee; Joo-Hang Kim; Yong Wha Moon
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

2.  Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.

Authors:  Margaret von Mehren; Michael C Heinrich; Hongliang Shi; Sergio Iannazzo; Raymond Mankoski; Saša Dimitrijević; Gerard Hoehn; Silvia Chiroli; Suzanne George
Journal:  BMC Cancer       Date:  2021-03-19       Impact factor: 4.430

3.  Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.

Authors:  Robin L Jones; César Serrano; Margaret von Mehren; Suzanne George; Michael C Heinrich; Yoon-Koo Kang; Patrick Schöffski; Philippe A Cassier; Olivier Mir; Sant P Chawla; Ferry A L M Eskens; Piotr Rutkowski; William D Tap; Teresa Zhou; Maria Roche; Sebastian Bauer
Journal:  Eur J Cancer       Date:  2021-01-16       Impact factor: 10.002
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.